Ocular Therapeutix (OCUL) Change in Acquisitions & Divestments (2015 - 2017)

Ocular Therapeutix's Change in Acquisitions & Divestments history runs 3 years deep, the most recent figure standing at $3.0 million for Q3 2017.

• On a quarterly basis, Change in Acquisitions & Divestments fell 79.57% year-over-year to $3.0 million in Q3 2017; TTM through Dec 2017 was $38.2 million, a 52.65% decrease from a year earlier, with the FY2017 full-year figure at $38.2 million, down 52.65% from the prior year.
• Change in Acquisitions & Divestments slipped to $3.0 million in Q3 2017 per OCUL's latest filing, from $22.7 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $30.0 million in Q3 2015 and bottomed at $3.0 million in Q3 2017.
• The 3-year median for Change in Acquisitions & Divestments is $16.0 million (2016), against an average of $18.2 million.
• Across the five-year window, Change in Acquisitions & Divestments increased 6.67% in 2016 and sank 79.57% in 2017, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $15.0 million in 2015, then climbed by 6.67% to $16.0 million in 2016, then tumbled by 81.25% to $3.0 million in 2017.
• Per Business Quant, the three latest OCUL Change in Acquisitions & Divestments figures stand at $3.0 million (Q3 2017), $22.7 million (Q2 2017), and $12.5 million (Q1 2017).